Union Conference to Feature Promising Findings from TB Alliance on Novel TB Drug Candidate Sorfequiline and the BPaL DR-TB Regimen

Data to be presented supports sorfequiline’s long-term outcomes data from the Phase 2 study NC-009, use in pregnant people, and early nonclinical proof of concept data in long-acting injectable (LAI) treatments

NEW YORK (November 16, 2026) —TB Alliance will present new findings on sorfequiline, its promising new investigative compound for tuberculosis (TB), and data on how BPaL (bedaquiline + pretomanid + linezolid) performed when used to treat drug-sensitive TB, at the Union Conference on Lung Health 2026, taking place November 17-20 in Rio de Janeiro, Brazil. The conference is the largest global gathering of TB researchers and advocates.

The sorfequiline findings support its potential use in TB drug regimen development inclusive of pregnant people, as a path to shorten treatment for drug-resistant TB, and to anchor Long-Acting Injectable (LAI) treatments. Eight presentations in total will feature TB Alliance research, including preclinical findings on a new investigational compound, TBAJ-587.

With drug resistance continuing to rise, TB Alliance is working to develop drugs and regimens to further shorten treatment time, while supporting countries to rapidly adopt the newest TB treatments.

“Our progress with sorfequiline and TBAJ-587 reflects the promise of TB Alliance’s pipeline to deliver shorter, simpler, and more effective TB treatments,” said Dr. Lynn Connolly, Chief Medical Officer at TB Alliance. “The Union Conference is an important opportunity to share emerging findings and to hear from clinicians, researchers, and impacted communities about how we can translate scientific advances into treatments that better meet the needs of people living with TB.” TB Alliance research will be presented at the Union Conference in the following sessions: